RASSF2 Antibody

1. Results showed that in the endometrial adenocarcinoma (OEA group) and ovarian clear cell carcinoma (OCC group) groups, the methylation degrees of the RASSF2A promoter were obviously higher than that of the other two groups. The expression level of RASSF2A mRNA in the OEA and OCC groups was lower than that of the other two groups. PMID: 29504361
2. we confirmed that the RASSF2-PAR-4 axis was mainly responsible for miR-7 functions in CAFs using bioinformatics methods. Overexpression of miR-7 in CAFs led to down-regulation of RASSF2, which dramatically decreased the secretion of PAR-4 from CAFs and then enhanced the proliferation and migration of the co-cultured cancer cells. PMID: 27901488
3. Results suggest that down-regulation of RASSF2, and RASSF6 is a tumor-specific phenomenon and their inactivation through CpG island methylation may play important roles in gastric cardia carcinogenesis. PMID: 26456015
4. The statistically most significant association rs4813720 correlates with RASSF2 expression and may play a significant role in childhood ALL etiology. PMID: 27861356
5. RASSF2 may be an important molecular marker for carcinogenesis, prognosis and progression in gastric cancer PMID: 26459248
6. RASSF2 gene is differently methylated in luminal and non-luminal tumors and is a promising suppressor gene with clinical involvement in breast cancer PMID: 26284587
7. our results suggest that RASSF2 may function as a tumor suppressor gene PMID: 26482475
8. We conclude that EPB41L3, RASSF2 and TSP-1 genes are involved in the pathogenesis of diffuse gliomas PMID: 25621889
9. Promoter hypermethylation of RASSF2A is observed in cervical cancer, while not in normal cervical tissues. PMID: 24605823
10. Epigenetic inactivation of RASSF2A through aberrant promoter methylation may play an important role in the pathogenesis of epithelial ovarian cancer. PMID: 24606436
11. results suggest that both RASSF1A and RASSF2 are novel epigenetically inactivated tumor suppressor genes in Ewing sarcoma and RASSF2 methylation may have prognostic implications for ES patients PMID: 23887284
12. our results suggest that RASSF2 potentially functions as a new tumor-suppressor gene that is inactivated through hypermethylation in cervical cancer PMID: 23542458
13. Promoter hypermethylation of RASSF2A is observed in pancreatic ductal adenocarcinoma, while not in normal pancreatic tissue. PMID: 21792082
14. Hypermethylation of RASSF2 gene is associated with advanced gastric cancer. PMID: 21409489
15. Sp1-mediated RASSF2A gene transcription is activated by p300 through histone acetylation, and this activation plays an important role in inducing late apoptosis. PMID: 20716062
16. Results suggest that RASSF2 encodes a novel epigenetically inactivated candidate tumor suppressor gene in thyroid carcinogenesis. PMID: 20920251
17. Aberrant methylation of the RASSF2A gene with the subsequent loss of RASSF2A expression plays an important role in the pathogenesis of hepatocellular carcinoma. PMID: 19513612
18. Data show that RASSF2 forms a direct and endogenous complex with prostate apoptosis response protein 4 (PAR-4) and that this interaction is regulated by K-Ras and is essential for the full apoptotic effects of PAR-4. PMID: 20368356
19. these findings indicate that MST1 is a major determinant of RASSF2 protein stability, and suggest that RASSF2 acts in a complex manner that extends beyond simple protein-protein association to play an important role in MST1 regulation. PMID: 19962960
20. RASSF2 is a new member of the RASSF1 family of Ras effectors/tumor suppressors that exhibits a specificity for interacting with K-Ras PMID: 12732644
21. In colonic neoplsms epigenetic (RASSF2A) and genetic (K-ras) changes are mutually exclusive and provide alternative pathways for affecting Ras signalling. PMID: 15806169
22. RASSF2 is a novel tumor suppressor gene that regulates Ras signaling and plays a pivotal role in the early stages of colorectal tumorigenesis. PMID: 16012945
23. RASSF2 is silenced by hypermethylation near the transcription start site in gastric cancer PMID: 16265349
24. Inactivation of RASSF2A by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma PMID: 17013896
25. Hypermethylation of the RASSF2A promoter and K-ras/BRAF mutations is associated with microsatellite-stable colorectal cancers PMID: 17013898
26. Transport of Ras effector superfamily proteins into the nucleus/nucleolus may play a vital role in modulating Ras-mediated cell proliferation during tumorigenesis. PMID: 17320110
27. Aberrant methylation of the RASSF2 gene with the subsequent loss of RASSF2 expression plays an important role in the pathogenesis of lung cancers. PMID: 17549418
28. A novel methylation marker for multiple malignancies; suppresses breast tumor cell growth in vitro and in vivo. PMID: 17891178
29. epigenetic inactivation of RASSF2 plays an important role in oral squamous cell carcinoma tumorigenesis PMID: 18294275
30. The epigenetic silencing of tumor suppressor genes involved in the Ras/PI3K/AKT pathway plays an important role in oral squamous cell carcinoma radioresistance PMID: 19509163
31. MST2 and RASSF2 form an active complex in vivo, in which RASSF2 is maintained in a phosphorylated state and protects MST2 from degradation and turnover PMID: 19525978
32. Data provide evidence that MAPK/ERK-2 mediated phosphorylation regulates nucleo-cytoplasmic transport and cell growth arrest activity of RASSF2. PMID: 19555684
33. Tumor-specific methylation of APC, MGMT, RASSF2A, and Wif-1 genes might be a valuable biomarker in plasma for the early detection of colorectal cancer. PMID: 19773381

Show More

Hide All

HGNC: 9883

OMIM: 609492

KEGG: hsa:9770

STRING: 9606.ENSP00000368684

UniGene: Hs.631504